Results 211 to 220 of about 151,098 (403)
State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases
ABSTRACT Pediatric rare diseases present unique challenges for drug development due to small patient populations, ethical constraints on clinical trial design, and limited prospectively defined natural history data. Model‐Informed Drug Development (MIDD) has emerged as a powerful paradigm to address these challenges by leveraging quantitative methods ...
Rajesh Krishna +4 more
wiley +1 more source
Seizure treatment in children: can intranasal midazolam be used without an atomizer? [PDF]
Rosa KD +7 more
europepmc +1 more source
ABSTRACT Efavirenz induces and inhibits multiple drug‐metabolizing enzymes, contributing to significant drug–drug interactions. This study quantified the impact of multiple doses of efavirenz on CYP3A activity via midazolam metabolism using a population pharmacokinetic approach.
Kimberly S. Collins +6 more
wiley +1 more source
Association between the use of midazolam, fentanyl, propofol, ketamine, and dexmedetomidine and the incidence of delirium in elderly patients in intensive care units: a systematic review. [PDF]
Santos WSD +4 more
europepmc +1 more source
ABSTRACT Isavuconazole is a broad‐spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co‐administration of isavuconazole with anticancer drugs–limited by the availability of clinical drug–drug interaction (DDI) data in ...
Theunis C. Goosen +6 more
wiley +1 more source
Remimazolam as a Novel Option for Procedural Sedation: A Narrative Review. [PDF]
Ziembicki H +5 more
europepmc +1 more source
Midazolam-Morphine Sedative Interaction in Patients
Mark Tverskoy +4 more
openalex +1 more source

